抗血管內皮生長因子於青光眼手術之運用

Application of Anti-Vegf (Vascular Endothelial Growth Factor) in Glaucoma Surgery

吳秀琛(Shiu-Chen Wu)

《中華民國眼科醫學會雜誌》 50卷2期 (2011/06) Pp. 262-266

https://doi.org/10.30048/ACTASOS.201106.0006

摘要

血管內皮生長因子（Vascular Endothelial Growth Factor‚VEGF）是一種當全身組織缺氧時引發刺激生成的cytokine，以促進血管生成、進而增加血液的供應；它是眼科新生血管疾病中很重要的血管生成因子，因此眼科醫學界一直希望研究抗血管內皮生長因子，用以治療威脅視力的各種眼睛新生血管疾病。Bevacizumab（Avastin）是一種由人體抗原製成的抗血管內皮生長因子單株抗體，雖然沒有經過正式認証用於眼科新生血管疾病，卻已經逐漸被運用於眼科的臨床治療。Ranibizumab（Lucentis）則是經過美國食品藥物管制局核定用於眼科老年黃斑病變引發之脈絡膜新生血管疾病。抗血管內皮生長因子已初步有效的被運用在新生血管青光眼、青光眼小樑網切除手術、及小樑網切除術後濾泡結痂修復手術。然而未來仍需針對其作用時效、使用方式與時機等做進一步臨床研究，才能了解抗血管內皮生長因子是否能真正在青光眼手術的臨床應用有助益。

並列摘要

Vascular Endothelial Growth Factor (VEGF) is a hypoxia-inducible cytokine involved in the formation of vessels throughout the body. It is an important angiogenic factor in ocular neovasculization. Bevacizumab (Avastin) is a humanized anti-VEGF-A monoclonal antibody and has been utilized extensively as an off-label treatment for ocular neovascular disease, including neovascular glaucoma. Ranibizumab (Lucentis) has been approved by the FDA for treating choroidal neovascular membranes related to AMD.The application of anti-VEGF in glaucoma surgery has recently been proposed. Anti-VEGF has been found to be useful in neovascular glaucoma, augmented trabeculectomy and revision of failing blebs. It is important to understand the duration of action, route of application, timing of injection, and dose and safety profile.

並列關鍵字

Vascular Endothelial Growth Factor ； Neovascular Glaucoma ； Trabeculectomy